| Literature DB >> 34436269 |
Xiaodan Chen1, Liying Ni1, Xiaoting Fu1, Lei Wang1, Delin Duan2,3, Luqiang Huang4, Jiachao Xu1, Xin Gao1.
Abstract
Seaweed of Saccharina japonica is the most abundantly cultured brown seaweed in the world, and has been consumed in the food industry due to its nutrition and the unique properties of its polysaccharides. In this study, fucoidan (LJNF3), purified from S. japonica, was found to be a novel sulfated galactofucan, with the monosaccharide of only fucose and galactose in a ratio of 79.22:20.78, and with an 11.36% content of sulfate groups. NMR spectroscopy showed that LJNF3 consists of (1→3)-α-l-fucopyranosyl-4-SO3 residues and (1→6)-β-d-galactopyranose units. The molecular mechanism of the anti-inflammatory effect in RAW264.7 demonstrated that LJNF3 reduced the production of nitric oxide (NO), and down-regulated the expression of MAPK (including p38, ENK and JNK) and NF-κB (including p65 and IKKα/IKKβ) signaling pathways. In a zebrafish experiment assay, LJNF3 showed a significantly protective effect, by reducing the cell death rate, inhibiting NO to 59.43%, and decreasing about 40% of reactive oxygen species. This study indicated that LJNF3, which only consisted of fucose and galactose, had the potential to be developed in the biomedical, food and cosmetic industries.Entities:
Keywords: RAW 264.7; Saccharina japonica; anti-inflammation; galactofucan; structure; zebrafish
Mesh:
Substances:
Year: 2021 PMID: 34436269 PMCID: PMC8398701 DOI: 10.3390/md19080430
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1DEAE-Sepharose Fast Flow anion-exchange chromatography for the purification of LJN.
Chemical composition, monosaccharide composition and molecular weight of LJNF1, LJNF2 and LJNF3.
| Sample | Total Sugar (%) | Sulfate (%) | Phenol (%) | Protein (%) | Monosaccharide Composition (%) | Molecular Weight (kDa) | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Rhamnose | Fucose | Xylose | Mannose | Galactose | Glucose | ||||||
| LJNF1 | 71.7 ± 0.25 | 9.31 ± 0.33 | 0.05 ± 0.01 | 0.07 ± 0.02 | 0.95 | 39.97 | 3.76 | 10.41 | 39.24 | 5.67 | 2113 |
| LJNF2 | 75.58 ± 0.53 | 8.42 ± 0.44 | 0.12 ± 0.01 | ND | 1.56 | 45.67 | 7.41 | 21.79 | 15.03 | 8.54 | 324.3 |
| LJNF3 | 69.12 ± 0.94 | 11.36 ± 0.42 | ND | ND | ND | 79.22 | ND | ND | 20.78 | ND | 261.7 |
ND: not detected.
Monosaccharide composition, sulfate group, molecular weight and biological activity of galactofucan in brown algae in recent years.
| Source of Algae | Monosaccharide Composition | Sulfate Group | Molecular Weight | Biological Activities | Reference | |
|---|---|---|---|---|---|---|
|
|
|
| 11.36 ± 0.42% | 261.7 KDa | Anti-inflammatory activity | this study |
|
|
| 21% | 13.7 KDa | Antiviral activity | [ | |
|
|
| 48.26% | ND | Growth-promoting activity of fibrocytes | [ | |
|
|
| 25.1% | 71 KDa | Anticancer | [ | |
|
| Fuc:Gal:Xyl = 86.1:11.1:2.8 | ND | 416,000 | Antitumour | [ | |
|
| Fuc:Gal:Man:Xyl = 49.9:44.1:5.3:1.1 | 23.2% | 1800 KDa | Antiviral activity | [ | |
|
| FucXyl:Gal:Glc:GalUA:Man = 14.9:1.0:16.8:1.7:3.9:6.3 | 26.7% | 527.3 KDa | Modify the intestinal microbiota | [ | |
|
| Fuc:Gal:Glu:Man:Rha:Xyl:GlcA = 16.67:31.90:2.50:6.36:1.46:2.20:6.82 | 27.13 ± 0.79% | 527.3 KDa | Hypolipidemic effect | [ | |
|
| Fuc:Gal:Man:Glc:Rha = 1:0.172:0.016:0.015:0.003 | 41.80% | ND | Neuron protective effect | [ | |
|
| Fuc:Gal:Man:Glc:Rha = 81.09:15.31:1.42:1.35:0.23 | 41.80% | 8.1 KDa | ND | [ | |
|
|
|
| 25.3% | 237.7 KDa | Anticancer | [ |
|
|
| 31.7% | 191 KDa | Anticancer | [ | |
|
|
| 35% | ND | Anticancer | [ | |
|
|
| 31.9% | 6.55 × 105 | Antiviral activity | [ | |
|
|
| ND | ND | Anti-angiogenic activity | [ | |
|
|
| 38.79% | 121.2 KDa | Anticancer | [ | |
|
| Fuc:Gal:Xyl = 36.0:19.1:1.7 | 33.7% | ND | ND | [ | |
|
| Man:Rha:GlcA:Glc:Gal:Xyl:Fuc = | 23.01% | 143.0 and 36.7 KDa | Anti-tumor and Anti-angiogenic activities | [ | |
|
| Man:Rha:GlcA:Glc:Gal:Xyl:Fuc = | 14.81% | 135 KDa | Neuroprotective activities | [ | |
|
| Fuc:Xyl:Gal:GlcA:Man = 1:0.03:0.24:0.02:0.02 | 45.02% | 151.2 KDa | ND | [ | |
|
|
|
| 24.0% | ND | Anticancer | [ |
|
| Fuc:Gal:Xyl = 47.5:47.3:5.2 | 28.3% | ND | Anticancer | [ | |
|
|
|
| ND | 992.9 × 103 g/mol | Immunological activity | [ |
|
|
| Fuc:Gal:Xyl = 1:0.27:0.01 | 39.85% | 99.2 KDa | Anti-complement activity | [ |
|
|
| Fuc:Gal:Xyl = 39.3:9.6:1.0 | 35.3% | 121 KDa | Anticoagulant | [ |
|
|
| Fuc:Gal:Xyl = 29.2:36.8:0.1 | ND | 35 KDa | Anti-oxidant and anti-inflammatory | [ |
|
|
| Fuc:Gal:Man:Glu = 39.8:36.7:17.4:6 | 18.6% | 317.5 and 8.5 KDa | Anticancer | [ |
|
|
| Fuc:Gal:Xyl:Man = 50.9:44.6:4.2:0.3 | ND | 1246 KDa | Antitumor | [ |
|
| Fuc:Gal:Rha = 54:45:1 | ND | 290 KDa | Antiviral activity | [ | |
|
|
|
| 29.5% | 8.5 KDa | Antiviral activity | [ |
|
|
| Fuc:Gal:Xyl = 1.0:2.0:0.5 | 36.36% | 21.5 KDa | Hemostatic Activities | [ |
|
| Fuc:Gal:Xyl = 1.0:2.0:0.5 | 15.0% | 21.5 KDa | Antitumor | [ | |
|
|
| Fuc:Gal:Man:GlcA = 70.2:19.8:7:3 | 23.8% | 160 KDa | ND | [ |
|
|
| Fuc:Gal:Man:Rha:Xyl:Glc = 1:0.83:0.01:0.05:0.06 | 18.9% | ND | Anticancer | [ |
|
|
| Fuc:Gal:Man:Xyl:Glc:GlcA = 1:0.35:0.05: 0.03:0.01:0.06 | 32.5% | 258 KDa | Antitumor | [ |
ND: not detected.
Figure 2FTIR spectrum analysis of LJNF3.
1H and 13C NMR data for LJNF3.
| Residue | Name | 1H and 13C Chemical Shifts (ppm) | |||||
|---|---|---|---|---|---|---|---|
| A | →3)-α- | H-1 | H-2 | H-3 | H-4 | H-5 | H-6 |
| 5.05 | 3.93 | 4.52 | 4.25 | 3.97 | 1.20 | ||
| C-1 | C-2 | C-3 | C-4 | C-5 | C-6 | ||
| 100.77 | 65.56 | 72.36 | 80.08 | 66.85 | 19.97 | ||
| B | →6)-β- | H-1 | H-2 | H-3 | H-4 | H-5 | H-6 |
| 4.46 | 3.55 | 3.72 | 3. 98 | 3.89 | 3.84 | ||
| C-1 | C-2 | C-3 | C-4 | C-5 | C-6 | ||
| 104.25 | 72.77 | 73.70 | 69.85 | 74.21 | 65.75 | ||
Figure 3The 1H (a), 13C (b), COSY (c), HSQC (d) and HMBC (e) spectrum of LJNF3.
Figure 4Effect of LJNF3 on RAW 264.7 cell viability (a) and NO production (b). Values correspond to mean ± SD of three independent experiments. Different letters indicate significant difference (p < 0.05) via Tukey’s multiple range test.
Figure 5Effect of LJNF3 on TNF-α (a), IL-1β (b) and IL-6 (c) protein levels in LPS-stimulated RAW 264.7 cells. Values correspond to mean ± SD of three independent experiments. Different letters indicate significant difference (p < 0.05) via Tukey’s multiple range test.
Figure 6Effects of LJNF3 on the expression of iNOS (a) and COX-2 (b) in LPS-induced RAW 264.7 cells. Values correspond to mean ± SD of three independent experiments. Different letters indicate significant difference (p < 0.05) via Tukey’s multiple range test.
Figure 7Effects of LJNF3 on the MAPK and NF-κB signaling pathways in LPS-stimulated RAW 264.7 cells. (a) p-ERK/ERK; (b) p-JNK/JNK; (c) p-p38/P38; (d) p-P65; and (e) p-IKKα/IKKβ. Values correspond to mean ± SD of three independent experiments. Different letters indicate significant difference (p < 0.05) via Tukey’s multiple range test.
Figure 8Effects of LJNF3 on LPS-induced survival rate (a) and heart-beating rate (b) in zebrafish embryos. Values correspond to mean ± SD of three independent experiments. Different letters indicate significant difference (p < 0.05) via Tukey’s multiple range test.
Figure 9Inhibitory effects of LJNF3 on LPS-induced cell death (a), ROS production (b), and NO production (c) in zebrafish embryos. Values correspond to mean ± SD of three independent experiments. Different letters indicate significant difference (p < 0.05) via Tukey’s multiple range test.